{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:31:26Z","timestamp":1784748686575,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.dld.2016.12.008","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:32:15Z","timestamp":1482453135000},"page":"368-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["French national consensus clinical guidelines for the management of Crohn\u2019s disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bonnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Hag\u00e8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.12.008_bib0005","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.12.008_bib0010","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 Guide Affection de longue dur\u00e9e Maladie de Crohn. 2008."},{"key":"10.1016\/j.dld.2016.12.008_bib0015","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.12.008_bib0020","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ibd.21870","article-title":"Recommendations for the treatment of Crohn\u2019s disease with tumor necrosis factor antagonists: an expert consensus report","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2016.12.008_bib0025","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn\u2019s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D\u2019Haens","year":"2011","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.12.008_bib0030","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of inflammatory bowel disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease","volume":"43","author":"Orlando","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2016.12.008_bib0035","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.12.008_bib0040","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2036.2006.02974.x","article-title":"The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort","volume":"24","author":"Ho","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.12.008_bib0045","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.3748\/wjg.v20.i12.3146","article-title":"Immunosuppressive therapies for inflammatory bowel disease","volume":"20","author":"Zenlea","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.12.008_bib0050","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn\u2019s disease","author":"Behm","year":"2008","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.dld.2016.12.008_bib0055","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.12.008_bib0060","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2016.12.008_bib0065","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.12.008_bib0070","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.crohns.2009.09.009","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: special situations","volume":"4","author":"Van Assche","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.12.008_bib0075","first-page":"166","article-title":"Management of anoperineal lesions in Crohn\u2019s disease","volume":"29","author":"Godeherge","year":"2005","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1016\/j.dld.2016.12.008_bib0080","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: definitions and diagnosis","volume":"4","author":"Van Assche","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.12.008_bib0085","article-title":"European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","author":"Gomoll\u00f3n","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2016.12.008_bib0090","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 Guide m\u00e9thodologique. Elaboration de recommandations de bonne pratique. M\u00e9thode \u00abRecommandations par consensus formalis\u00e9 \u00bb. 2010."},{"issue":"Suppl. 3","key":"10.1016\/j.dld.2016.12.008_bib0095","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000342608","article-title":"Clinical risk factors for complicated disease: how reliable are they","volume":"30","author":"Zallot","year":"2012","journal-title":"Digestive Diseases"},{"key":"10.1016\/j.dld.2016.12.008_bib0100","article-title":"Crit\u00e8res d\u2019efficacit\u00e9 d\u2019un traitement par adalimumab chez les patients atteints de maladie de Crohn avec st\u00e9nose symptomatique de l\u2019intestin gr\u00eale: cohorte multicentrique, prospective observationnelle (CREOLE)","author":"Bouhnik","year":"2015","journal-title":"JFHOD"},{"key":"10.1016\/j.dld.2016.12.008_bib0105","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.12.008_bib0110","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.dld.2016.03.029","article-title":"French national consensus clinical guidelines for the management of ulcerative colitis","volume":"48","author":"Peyrin-Biroulet","year":"2016","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2016.12.008_bib0115","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto Consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.12.008_bib0120","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.dld.2015.12.016","article-title":"Expert consensus paper on the use of vedolizumab for the management of patients with moderate-to-severe inflammatory bowel disease","volume":"48","author":"Armuzzia","year":"2016","journal-title":"Digestive and Liver Disease"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816308283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816308283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T17:25:23Z","timestamp":1536168323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816308283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1590865816308283"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.12.008","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French national consensus clinical guidelines for the management of Crohn\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}